Videos

Beena Wood, Qinecsa, saw 2025 as an AI superposition in which pharmacovigilence needed better data foundations and regulation.

Realizing the Potential of Enterprise AI within the Global Pharmacovigilance Domain

Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.

The Critical Need for Digital Transformation in the Peptide and API Sectors

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

Gene Therapy, Rare Diseases, and Transfer RNA

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and evolving drug development landscape.

Behind the Headlines Episode 31: Optimism, Opportunity, Optimization of COGs & Organizational Streamlining

Mike Stenberg, LGM Pharma, explains how faster FDA approvals under CNPV shift bottlenecks to production, requiring onshoring and earlier supply chain risk.

Navigating Financial and Opportunity Risks in Accelerated Drug Launches

Laine Mello, director of marketing at Ecolab Bioprocessing, reflects on how the use of digital technologies expanded in the pharma industry in 2025 and how new complex molecules will continue to drive innovation in 2026.

Industry Outlook 2026: Trends Transitioning from 2025 into 2026 

Raj Puri, chief commercial officer at Argonaut Manufacturing, talks about how navigating the pressure to respond to tariffs with investments and keeping a robust and qualified staff are key moves in the new year.

Making Smart Decisions and Investments in Trained Staff Key to 2026 Success

Saharsh Davuluri, Neuland Labs, discusses the move from labor to knowledge arbitrage for API manufacturers, using AI tools to empower scientists in process development.

Advancing Pharmaceutical Quality through Integrated Digital Systems and Collaborative Scientific Innovation

Remco Munnik, Arcana, details pharma's shift to data-first operations, AI adoption, and robust data stewardship.

The Evolution of Data-First Regulatory Operations

Saharsh Davuluri, Neuland Labs, covers M&A blending, geopolitical shifts, and supply chain de-risking in this look back at pharma in 2025.

PharmTech Videos